LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

Home・Akciju saraksts・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Atvērts

3.69 5.43

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.45

Max

3.75

Galvenie mērījumi
By Trading Economics
Ienākumi	44M -26M
Pārdošana	-5.8M 42M
Peļņas marža	-61.388
Darbinieki	550
EBITDA	44M -22M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+16.28% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	162M 1.2B
Iepriekšējā atvēršanas cena	-1.74
Iepriekšējā slēgšanas cena	3.69

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

2.02 / 2.115 Atbalsts un pretestība

Maravai LifeSciences Holdings Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. dec. 23:21 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025. g. 3. dec. 23:14 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025. g. 3. dec. 22:01 UTC

Galvenie tirgus virzītāji

Costco Wholesale Reports Higher Monthly Sales

2025. g. 3. dec. 21:38 UTC

Peļņas

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025. g. 3. dec. 23:59 UTC

Tirgus saruna

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025. g. 3. dec. 23:13 UTC

Tirgus saruna

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025. g. 3. dec. 23:10 UTC

Peļņas

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025. g. 3. dec. 23:08 UTC

Tirgus saruna

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025. g. 3. dec. 23:06 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025. g. 3. dec. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy PC Financial From Loblaw for About $573.5M

2025. g. 3. dec. 22:45 UTC

Tirgus saruna

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025. g. 3. dec. 22:20 UTC

Peļņas

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025. g. 3. dec. 22:19 UTC

Peļņas

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025. g. 3. dec. 22:17 UTC

Peļņas

Salesforce Working to Add Voice to Agentforce, CEO Says

2025. g. 3. dec. 22:16 UTC

Peļņas

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025. g. 3. dec. 22:15 UTC

Peļņas

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025. g. 3. dec. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025. g. 3. dec. 22:09 UTC

Iegādes, apvienošanās, pārņemšana

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025. g. 3. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 3. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. dec. 21:49 UTC

Peļņas

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:23 UTC

Peļņas

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025. g. 3. dec. 21:19 UTC

Peļņas

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:06 UTC

Peļņas

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:04 UTC

Peļņas

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025. g. 3. dec. 21:04 UTC

Peļņas

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025. g. 3. dec. 21:03 UTC

Peļņas

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Salīdzinājums

Cenas izmaiņa

Maravai LifeSciences Holdings Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

16.28% augšup

Prognoze 12 mēnešiem

Vidējais 4 USD 16.28%

Augstākais 4 USD

Zemākais 4 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.02 / 2.115Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.